Business
Kura Oncology Eyes 2026 as Pivotal Year Amid Pipeline Expansion and Analyst Scrutiny
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.